JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
QUICK SEARCH:   [advanced]


     

Anesth Analg 1986; 65:245-251
© 1986 International Anesthesia Research Society
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bencini, A. F.
Right arrow Articles by Agoston, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bencini, A. F.
Right arrow Articles by Agoston, S.

Disposition and Urinary Excretion of Vecuronium Bromide in Anesthetized Patients with Normal Renal Function or Renal Failure

Anton F. Bencini, MD, FFARCS, Arnold H. J. Scaf, PhD, Yung J. Sohn, MD, Claude Meistelman, MD, André Lienhart, MD, Ursula W. Kersten, Sylvia Schwarz, MD, and Sandor Agoston, MD, PhD

Institutes of Anesthesiology and Clinical Pharmacology, State University of Groningen, The Netherlands, the Department of Anesthesiology, C.H.U. Pitié Salpètrière, Paris, France, and the Department of Anesthesiology, University Hospital, Vienna, Austria.

Abstract

The effect and plasma concentrations of vecuronium bromide were measured in normal patients after an intravenous dose of 50, 100, or 150 µg/kg and in patients with renal failure after 50 or 100 µg/kg. Urinary excretion of vecuronium was studied in normal patients after the 150 µg/kg dose. Pharmacokinetic parameters of patients with or without renal failure were similar. No metabolites of vecuronium were found in the plasma. Twenty percent of vecuronium was excreted unchanged in the urine; 5% as the 3-hydroxy derivative. No other metabolites of vecuronium were found in the urine. Increasing doses of vecuronium shortened the onset, but prolonged the duration of action and the recovery rate, to a similar extent in Patients with or without renal failure. It was concluded that the disposition of vecuronium was best described by a three compartment model. Both the disposition and the effect of vecuronium are only marginally disturbed by renal failure.

Key Words: NEUROMUSCULAR RELAXANTS—vecuronium




This article has been cited by other articles:


Home page
 Br J AnaesthHome page
R. G. Craig and J. M. Hunter
Recent developments in the perioperative management of adult patients with chronic kidney disease
Br. J. Anaesth., September 1, 2008; 101(3): 296 - 310.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
J. H. Proost, L. I. Eriksson, R. K. Mirakhur, G. Roest, and J. M. K. H. Wierda
Urinary, biliary and faecal excretion of rocuronium in humans
Br. J. Anaesth., November 1, 2000; 85(5): 717 - 723.
[Abstract] [Full Text] [PDF]


Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 1986 by the International Anesthesia Research Society.